Replimune Group, Inc. (NASDAQ: REPL) is a clinical-stage biotechnology company focused on the discovery and development of oncolytic immuno-gene therapies designed to harness the body’s own immune system to fight cancer. The company employs proprietary technology to engineer viruses capable of selectively infecting and destroying tumor cells, while simultaneously stimulating an anti-tumor immune response. Replimune’s approach centers on genetically modified herpes simplex virus vectors that deliver immunomodulatory genes directly into the tumor microenvironment.
The company’s lead clinical candidates include RP1, an oncolytic immunotherapy armed with a granulocyte-macrophage colony-stimulating factor (GM-CSF) gene, and RP2, which encodes both GM-CSF and an immune checkpoint inhibitor targeting PD-1. These programs are being evaluated across multiple solid tumor indications, including melanoma, cutaneous squamous cell carcinoma and basal cell carcinoma. Replimune also maintains discovery-stage assets such as RP3, further illustrating its commitment to a broad pipeline of next-generation oncolytic therapies.
Founded in 2018 by industry veterans with deep expertise in viral immunotherapy, Replimune is led by President and Chief Executive Officer Daniel D. Y. Ma, Ph.D., whose prior experience includes leadership roles at Amgen and other biopharmaceutical companies. The company’s scientific strategy is guided by co-founder and Chief Scientific Officer Ian W. Taylor, Ph.D., and supported by a multidisciplinary management team with backgrounds in oncology research, clinical development and regulatory affairs.
Headquartered in Woburn, Massachusetts, Replimune conducts clinical trials and research collaborations across the United States and in Europe. By combining targeted viral delivery with engineered immune stimulators, the company aims to establish a new class of cancer immunotherapies capable of achieving durable responses in patients with advanced solid tumors.
AI Generated. May Contain Errors.
